Financials data is unavailable for this security.
View more
Year on year Ligand Pharmaceuticals Inc had revenues fall -33.09% from 196.25m to 131.31m, though the company grew net income from a loss of 33.36m to a gain of 52.15m.
Gross margin | 91.82% |
---|---|
Net profit margin | 31.57% |
Operating margin | -14.53% |
Return on assets | 5.19% |
---|---|
Return on equity | 5.85% |
Return on investment | 5.35% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Ligand Pharmaceuticals Inc fell by 22.05m. However, the company earned 49.58m from its operations for a Cash Flow Margin of 37.75%. In addition the company used 11.68m on investing activities and also paid 59.95m in financing cash flows.
Cash flow per share | 4.24 |
---|---|
Price/Cash flow per share | 28.66 |
Book value per share | 42.82 |
---|---|
Tangible book value per share | 16.92 |
More ▼
Balance sheet in USDView more
Current ratio | 16.82 |
---|---|
Quick ratio | 15.81 |
Total debt/total equity | 0.00002 |
---|---|
Total debt/total capital | 0.00002 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -12.71 |
---|---|
EPS (TTM) vs TTM 1 year ago | -40.66 |